On this page
What each program costs in Wyoming
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the Wyoming Employees' Group Insurance (EGI) cover GLP-1s for weight loss?
Since January 1, 2026 Wyoming's Employees' Group Insurance covers anti-obesity GLP-1s beyond its former six-month lifetime limit for Cigna/CVS Caremark plan members who join a CVS Caremark weight management program, meet BMI-based guidelines and get prior authorization.
Wyoming Administration & Information, Employees' Group Insurance
EGI says its CVS Caremark weight management program, started January 1, 2026, extends GLP-1 coverage past the old six-month lifetime limit.
“This program will allow for expanded coverage of anti-obesity GLP-1 medications beyond the existing six-month lifetime limit.”
https://ai.wyo.gov/divisions/human-resources/group-insurance/weight-management-glp1 · read Oct 29, 2026
Wyoming Administration & Information, Employees' Group Insurance
Joining the program is a condition of coverage.
“Participating in the program is required for coverage of the medication.”
https://ai.wyo.gov/divisions/human-resources/group-insurance/weight-management-glp1 · read Oct 29, 2026
Wyoming Administration & Information, Employees' Group Insurance
The medication also needs prior authorization.
“A Prior authorization is required for the medication and you will receive information from CVS direct on how to enroll in the weight management program.”
https://ai.wyo.gov/divisions/human-resources/group-insurance/weight-management-glp1 · read Oct 29, 2026
Does Wyoming Medicaid cover GLP-1s for weight loss?
Not covered for weight loss
Wyoming's P&T Committee minutes from May 2026 say weight loss agents are not currently covered, and the preferred drug list ties Wegovy to MASH and lists GLP-1 criteria for obstructive sleep apnea. Read from state documents Nov 6, 2026.
What Wyoming Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Wyoming Department of Health, Division of Healthcare Financing.
WegovyNo
PDL requires a MASH diagnosis and refers to other criteria for cardiovascular disease. February 2026 minutes mention approval of a GLP-1 for weight loss in children with dietary counseling, so the answer may differ for children.
“This is an FYI only. Weight loss agents are not currently covered.”
Wyoming Medicaid P&T Committee (WYDUR, University of Wyoming, for the Wyoming Department of Health) · No effective date on the document · read Nov 6, 2026
“Wegovy will require diagnosis of MASH.”
Wyoming Medicaid Preferred Drug List · Effective Jan 1, 2026 · read Nov 6, 2026
“dietary counseling should be required prior to approval of a GLP-1 agent for weight loss in pediatric patients”
Wyoming Medicaid P&T Committee (WYDUR, University of Wyoming, for the Wyoming Department of Health) · No effective date on the document · read Nov 6, 2026
ZepboundNo
PDL lists Zepbound and GLP-1 criteria for moderate to severe obstructive sleep apnea in adults with obesity. February 2026 minutes mention approval of a GLP-1 for weight loss in children with dietary counseling, so the answer may differ for children.
“This is an FYI only. Weight loss agents are not currently covered.”
Wyoming Medicaid P&T Committee (WYDUR, University of Wyoming, for the Wyoming Department of Health) · No effective date on the document · read Nov 6, 2026
“Client must have diagnosis of moderate to severe obstructive sleep apnea.”
Wyoming Medicaid Preferred Drug List · Effective Jan 1, 2026 · read Nov 6, 2026
“dietary counseling should be required prior to approval of a GLP-1 agent for weight loss in pediatric patients”
Wyoming Medicaid P&T Committee (WYDUR, University of Wyoming, for the Wyoming Department of Health) · No effective date on the document · read Nov 6, 2026
OzempicUnclear
Ozempic is listed in the GLP-1 class. No Wyoming document read says weight loss is excluded for this diabetes drug by name. The PDL requires a metformin trial, waived with ASCVD or risk factors, without stating a diagnosis, and the May 2026 minutes speak of weight loss agents as a group.
“This is an FYI only. Weight loss agents are not currently covered.”
Wyoming Medicaid P&T Committee (WYDUR, University of Wyoming, for the Wyoming Department of Health) · No effective date on the document · read Nov 6, 2026
“Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent”
Wyoming Medicaid Preferred Drug List · Effective Jan 1, 2026 · read Nov 6, 2026
MounjaroUnclear
Mounjaro is listed in the GLP-1 class. No Wyoming document read says weight loss is excluded for this diabetes drug by name. The PDL requires a metformin trial, waived with ASCVD or risk factors, without stating a diagnosis, and the May 2026 minutes speak of weight loss agents as a group.
“This is an FYI only. Weight loss agents are not currently covered.”
Wyoming Medicaid P&T Committee (WYDUR, University of Wyoming, for the Wyoming Department of Health) · No effective date on the document · read Nov 6, 2026
“Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent”
Wyoming Medicaid Preferred Drug List · Effective Jan 1, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Wyoming Department of Health, Division of Healthcare Financing documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
139 prescriptions
Ozempic and Mounjaro, 2025
1,139 prescriptions
Neighbours covering weight loss
0 of 6
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Wyoming Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Wyoming Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Wyoming Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Wyoming Medicaid pay for?
2,315 GLP-1 prescriptions in 2025, 51st of the 50 states and DC, with $2.2 million reimbursed before rebates. Counting the share other payers covered, $2.2 million.
Prescriptions, 2025
2,315
51st of 51
Medicaid paid
$2.2M
51st of 51, before rebates
Per prescription
$964
$1,051 nationally
Weight-loss brands
6.0%
22nd highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Wyoming is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 6.0% of Wyoming Medicaid's GLP-1 prescriptions in 2025 (139). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Trulicity was Wyoming Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Trulicity | 907 | 39% | $874,050 | $964 |
| Mounjaro | 624 | 27% | $634,821 | $1,017 |
| Ozempic | 515 | 22% | $488,264 | $948 |
| Zepboundapproved for weight management | 114 | 4.9% | $115,647 | $1,014 |
| Rybelsus | 53 | 2.3% | $51,706 | $976 |
| Liraglutide (generic) | 53 | 2.3% | $26,631 | $502 |
| Wegovyapproved for weight management | 25 | 1.1% | $27,771 | $1,111 |
| Victoza | 24 | 1.0% | $13,894 | $579 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Wyoming?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Wyoming and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 6 states next to Wyoming covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than Wyoming's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Wyoming | Not covered | 19 | $39/mo |
| Colorado | Not covered | 19 | $39/moWellmedr |
| Idaho | Not covered | 19 | $39/moWellmedr |
| Montana | Not covered | 19 | $39/moWellmedr |
| Nebraska | Not covered | 19 | $39/moWellmedr |
| South Dakota | Not covered | 19 | $39/moWellmedr |
| Utah | Not confirmed | 19 | $39/moWellmedr |






















